RESEARCH MONOGRAPH · KDC-MN-103

Nicotinamide Riboside (NR)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

77/100

Better-characterized cousin of NMN with cleaner PK data and a Brenner-lab pedigree

NR is the NAD+ precursor that actually has a clean human pharmacology story. Charles Brenner and colleagues identified the salvage pathway role, ChromaDex commercialized it, and the resulting twenty-plus published human trials make NR one of the better-studied NAD+ precursors at the pharmacokinetic level. The Trammell 2016 Nature Communications paper established that oral NR raises whole-blood NAD+ in humans, dose-dependently, with a clear PK profile.

Mechanistically NR enters cells via equilibrative nucleoside transporters, gets phosphorylated by NRK1/NRK2 to NMN, then gets adenylylated to NAD+. The salvage pathway from nicotinamide is intact in everyone, the question is just throughput. NR bypasses the rate-limiting NAMPT step that nicotinamide goes through, which is why dose-for-dose it tends to raise NAD+ more efficiently than equivalent nicotinamide. Whether NR or NMN ends up being functionally identical at the cellular level is partly the gut-versus-direct-transport question that's still partly open.

Clinical trial wise, NR has shown elevations in NAD+, modest signals on some inflammatory and metabolic markers, and largely null or small signals on muscle and cognitive endpoints in healthy aged adults. The disease-context trials (heart failure, Parkinson's, ALS) have been more interesting because the NAD+ deficit is larger in those populations and the response is correspondingly bigger.

What we like: the most rigorously characterized NAD+ precursor in humans, by a wide margin. Brenner's lab consistency, the safety database is now large, and the combination work with things like pterostilbene (the original Elysium product) or with senolytics or with exercise interventions is where it gets interesting.

What we dont like is the marketing creep about anti-aging effects that the trial data dont really support yet. NR raises NAD+, that part is established. Whether that translates to a meaningful aging phenotype shift in non-deficient humans is the unresolved part.

Sourcing: NR chloride (the predominant form) is well-characterized, ChromaDex's Niagen has the trial data behind it but generics from reputable suppliers are also fine if you have COAs. HPLC purity 98%+ is standard. Stability is okay if kept cool and dry. NR is more hygroscopic than NMN.

If you want to study NAD+ precursor biology and you want the most defensible PK data, NR is the molecule. If you want the bigger anti-aging hype cycle, NMN. The actual biology probably converges.

Evidence: 72
Mechanism: 82
Reliability: 75
Safety: 88
Sourcing: 82
Value: 70
Signal: 72
Staying power: 75

Plain-language summary Intrigue 70 / 100

Nicotinamide riboside (NR) is another NAD+ precursor that converts to NAD+ in the body. Sold as Niagen and Tru Niagen, it is one of the most extensively studied longevity supplements. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

NAD+ precursor

A NAD+ precursor sold as Niagen (Tru Niagen) with a more established human clinical trial record than NMN, marketed as a dietary supplement.

Abstract

Nicotinamide Riboside (NR; CAS 1341-23-7; molecular formula C11H15N2O5; molecular weight 255.25) is a vitamin B3 form that serves as a NAD+ precursor through the NRK kinase pathway. The compound is one phosphorylation step upstream of NMN in the salvage pathway. NR was discovered as a NAD+ precursor by Charles Brenner's group in 2004. The compound is sold as Niagen (Tru Niagen), with an established human clinical trial program demonstrating consistent plasma NAD+ elevation (50 to 200 percent over baseline) with oral supplementation. Clinical endpoint changes are modest; cardiovascular function improvements have been the most consistent finding. The compound is GRAS-affirmed and FDA-recognized as a dietary supplement. Reported research dose ranges in the literature are typically 250 to 1000 mg.

Mechanism of action

NAD+ precursor through NRK kinase pathway; more upstream than NMN.

Reported research dose ranges

250 to 1000 mg (reported research dose ranges in the literature).

References

Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes. Cell 2004.
Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-103

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Nicotinamide Riboside (NR)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs